

Approved



**Botswana**

**Country Operational Plan**

**FY 2016**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		62,651		62,651	175,000	237,651
USAID		9,508,229		9,508,229	7,625,625	17,133,854
DOD		0		0	1,358,000	1,358,000
PC		1,400,000		1,400,000	900,000	2,300,000
HHS/CDC	2,196,250	12,113,354		14,309,604	8,005,013	22,314,617
HHS/HRSA		3,067,000		3,067,000	1,578,799	4,645,799
State/AF		0		0	225,000	225,000
<b>Total</b>	<b>2,196,250</b>	<b>26,151,234</b>	<b>0</b>	<b>28,347,484</b>	<b>19,867,437</b>	<b>48,214,921</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		0	1,182,746					0	1,182,746
HBHC			1,761,309	300,000			2,225,455	0	4,286,764
HKID							3,395,315	0	3,395,315
HLAB		0	140,601				0	0	140,601
HMBL			24,485				0	0	24,485
HTXD			116,043				2,999	0	119,042
HTXS			4,492,973	1,610,000			243,986	0	6,346,959
HVAB							8,999	0	8,999
HVCT			2,365,859	585,000				0	2,950,859
HVMS	62,651	0	808,905		1,330,000		1,764,109	0	3,965,665

Approved



HVOP		0	202,929		70,000		267,272	0	<b>540,201</b>
HVSI			98,971				531,906	0	<b>630,877</b>
HVTB			2,156,832	572,000			452,016	0	<b>3,180,848</b>
MTCT			201,985					0	<b>201,985</b>
OHSS			8,442			0	610,173	0	<b>618,615</b>
PDCS			363,039				5,999	0	<b>369,038</b>
PDTX			384,485					0	<b>384,485</b>
	<b>62,651</b>	<b>0</b>	<b>14,309,604</b>	<b>3,067,000</b>	<b>1,400,000</b>	<b>0</b>	<b>9,508,229</b>	<b>0</b>	<b>28,347,484</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	4,239,645	0
HKID	3,368,319	0
HVTB	3,144,920	0
PDCS	360,000	0
<b>Total Technical Area Planned Funding:</b>	<b>11,112,884</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	120,000	0
HVSI	550,000	0
OHSS	500,000	0
<b>Total Technical Area Planned Funding:</b>	<b>1,170,000</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	1,100,000	0
HMBL	0	0
HVCT	2,885,000	0
HVOP	411,012	0
MTCT	177,500	0
<b>Total Technical Area Planned Funding:</b>	<b>4,573,512</b>	<b>0</b>

Approved



**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	100,000	0
HTXS	6,266,947	0
PDTX	360,000	0
<b>Total Technical Area Planned Funding:</b>	<b>6,726,947</b>	<b>0</b>



### Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,335
	Number of new ANC and L&D clients	16,335
	By: Known positives at entry	727
	By: Number of new positives identified	3,673
	Sum of Positives Status disaggregates	4,400
	Required only for DREAMS countries - By known positives: <15	
	Required only for DREAMS countries - By known positives: 15-19	
	Required only for DREAMS countries - By known positives: 20-24	
	Required only for DREAMS countries - By new positives: <15	
	Required only for DREAMS countries - By new positives: 15-19	
	Required only for DREAMS countries - By new positives: 20-24	



	Required only for DREAMS countries - Denominator: <15	
	Required only for DREAMS countries - Denominator: 15-19	
	Required only for DREAMS countries - Denominator: 20-24	
	Required only for DREAMS countries - Denominator: 25-49	
	Required only for DREAMS countries - Denominator: 50+	
	Required only for DREAMS countries - By known positives: 25-49	
	Required only for DREAMS countries - By known positives: 50+	
	Required only for DREAMS countries - By new positives: 25-49	
	Required only for DREAMS countries - By new positives: 50+	
	By Age (DREAMS SNU ONLY): <15	
	By Age (DREAMS SNU ONLY): 15-19	
	By Age (DREAMS SNU ONLY): 20-24	
	By Age (DREAMS SNU ONLY): 25-49	
	By Age (DREAMS SNU ONLY): 50+	
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a



	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	
	New on ART	16
	Already on ART at beginning of current pregnancy	0
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,335
	New on ART	1,404
	Already on ART at beginning of current pregnancy	2,775
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,576
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	2,141
	By Age: 15-19	6,989
	By Age: 20-24	4,392
	By Age: 25-29	2,135



	By Age: 30-49	1,220
	By Age: 50+	52
	Sum of age disaggregates (Prior to FY15)	13,574
	Sum of age disaggregates (FY15-Current)	16,929
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	9,728
	By circumcision technique: Device-based VMMC	1,025
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,335



	By Age: 0-60 Days	
	By Age: 2 months - 9 years	
	By Age: 10-14	200
	By Age: 15-19	532
	By Age: 20-24	262
	By Age: 25-49	141
	By Age: 25-29	
	By Age: 30-49	200
	By Age: 50+	
	Sum of Age disaggregations (Prior to FY15)	1,135
	Sum of age disaggregates (FY15-Current)	1,194
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	1,068
	By circumcision technique: Device-based VMMC	267
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients	



	who returned at least once for follow-up care within 14 days of device placement	
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,529
	Total number of people in the target population	5,529
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	



	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	205
	Aggregated Age/sex: 15+ Male	510
	Aggregated Age/sex: <15 Female	1,382
	Aggregated Age/sex: 15+ Female	3,432
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,620
	Total number of people in the target population	309,513
	Age/sex: 10-14 Male	



	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Age/sex: <15 Male	3,405
	Aggregated Age/sex: 15+ Male	3,269
	Aggregated Age/sex: <15 Female	3,541
	Aggregated Age/sex: 15+ Female	3,405
	KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required		5,081
Total estimated number of key population in the catchment area		7,257
By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that		0



	are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	742
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,339
	By key population type: Males who inject drugs ( Male PWID)	



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,062
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the	0



	catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	6,195
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	360,025
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	135
	Age/sex: 15-19 Male	191
	Age/sex: 20-24 Male	829
	Age/sex: 25-49 Male	334
	Age/sex: 50+ Male	11
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	0
	Age/sex: 15-19 Female	0
	Age/sex: 20-24 Female	0
	Age/sex: 25-49 Female	0
	Age/sex: 50+ Female	0
	Test Result by Age and Sex: Positive: 10-14 Male	4
	Test Result by Age and Sex: Positive: 15-19 Male	6
	Test Result by Age and Sex: Positive: 20-24 Male	25
	Test Result by Age and Sex: Positive: 25-49 Male	10
	Test Result by Age and Sex: Positive: 50+ Male	0
	Test Result by Age and Sex: Positive: 10-14 Female	0
	Test Result by Age and Sex: Positive: 15-19 Female	0
Test Result by Age and Sex: Positive: 20-24 Female	0	
Test Result by Age and Sex:	0	



	Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	0
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,099
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	96,515
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,516
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	206,730
	Test Result by Aggregated Age	



	and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	320
	Test Result by Aggregated Age and Sex: Positive 15+ Male	9,169
	Test Result by Aggregated Age and Sex: Positive <15 Female	514
	Test Result by Aggregated Age and Sex: Positive 15+ Female	17,314
	Test Result by Age: Positive: <1	0
	Test Result by Age: Positive: 1-9	0
	Age/sex: <1	0
	Age/sex: 1-9	0
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	41,513
	Service Delivery Point (Community): Mobile testing	54,553
	Service Delivery Point (Community): Other	16,473
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community)	



	by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	0
	Service Delivery Point (Facility): Outpatient	151,139
	Service Delivery Point (Facility): Pediatric	0
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	259
	Service Delivery Point (Facility): VCT	48,436
	Service Delivery Point (Facility): VMMC	1,500
	Service Delivery Point (Facility): PMTCT	8,851
	Service Delivery Point (Facility): TB Clinics	1,136
	Service Delivery Point (Facility): Index testing	0
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by	



	Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by	



	Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,723
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	
	Test Result by Age and Sex: Positive: 15-19 Female	
Test Result by Age and Sex: Positive: 20-24 Female		



	Test Result by Age and Sex: Positive: 25-49 Female	
	Test Result by Age and Sex: Positive: 50+ Female	
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,446
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,337
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,122
	Aggregated Age/sex - USE WITH	26,818



	HQ PERMISSION ONLY: 15+ Female	
	Test Result by Aggregated Age and Sex: Negative <15 Male	
	Test Result by Aggregated Age and Sex: Negative 15+ Male	
	Test Result by Aggregated Age and Sex: Negative <15 Female	
	Test Result by Aggregated Age and Sex: Negative 15+ Female	
	Test Result by Aggregated Age and Sex: Positive <15 Male	15
	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,421
	Test Result by Aggregated Age and Sex: Positive <15 Female	54
	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,041
	Test Result by Age: Positive: <1	
	Test Result by Age: Positive: 1-9	
	Age/sex: <1	
	Age/sex: 1-9	
	Service Delivery Point (Community): Index testing	
	Service Delivery Point (Community): Homebased testing	
	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	



	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	
	Service Delivery Point (Facility): Outpatient	31,235
	Service Delivery Point (Facility): Pediatric	
	Service Delivery Point (Facility): Malnutrition facilities	
	Service Delivery Point (Facility): Other PITC	
	Service Delivery Point (Facility): VCT	
	Service Delivery Point (Facility): VMMC	
	Service Delivery Point (Facility): PMTCT	3,255
	Service Delivery Point (Facility): TB Clinics	233
	Service Delivery Point (Facility): Index testing	
	Service Delivery Point (Facility) by Age: <15 Inpatient	



	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	



	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,583
	Total number of registered new and relapsed TB cases, during the reporting period.	5,583
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and	



	relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	196
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,002
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	199
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,186
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	



	cases, during the reporting period)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,340
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	0
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	0
	Sum of Age/Sex disaggregates	0
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female	



	25+	
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female	



	18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male	



	1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	486
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	5,232
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries	1,500



	served by PEPFAR OVC programs for children and families affected by HIV/AIDS	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	143
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	183
	Sum of Age/Sex disaggregates	326
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS	



	countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	



	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver	



	Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening	



	Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age	



	and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	



	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	



	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas 1-9	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,434
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,434
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	119
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,848
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,347
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	



	period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator:	



	<p>The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB</p>	



	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	19,964



	Screened for TB by Age/Sex: <15 Male	10
	Screened for TB by Age/Sex: 15+ Male	204
	Screened for TB by Age/Sex: <15 Female	9
	Screened for TB by Age/Sex: 15+ Female	935
	Screen Result: Screened Positive for TB	15
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	15
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	8
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	571
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	178,918
	Screened for TB by Age/Sex: <15 Male	1,145
	Screened for TB by Age/Sex: 15+ Male	67,099



	Screened for TB by Age/Sex: <15 Female	1,413
	Screened for TB by Age/Sex: 15+ Female	109,261
	Screen Results: Screened Positive for TB	7,511
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,511
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	5,198
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,254
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	



	By infants who received a virologic test within 2 months of birth	2,926
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,254
	Sum of Infant Age disaggregates	4,180
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	49
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	21
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,413
	Age/Sex: 15-19 Male	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	10
	Aggregated Age/Sex: 15+ Male	204
	Aggregated Age/Sex: <15 Female	9



	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,185
	Sum of Aggregated Age/Sex <15	19
	Sum of Aggregated Age/Sex 15+	1,389
	Sum of Aggregated Age/Sex disaggregates	1,408
	Age/Sex: <1	
	Age/Sex: <1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	178,918
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	



	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	3,269
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	65,286
	Aggregated Age/Sex: <15 Female	4,044
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	106,319
	Sum of Aggregated Age/Sex <15	7,313
	Sum of Aggregated Age/Sex 15+	171,605
	Sum of Aggregated Age/Sex disaggregates	178,918
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,230
	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	



	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	2
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	38
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	2
	Aggregated Grouping by Age/Sex: 15+ Female	407
	Sum of Aggregated Age/Sex disaggregates	449
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	34,950



	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	1,186
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	12,293
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	1,450
	Aggregated Grouping by Age/Sex:	



	1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	20,021
	Sum of Aggregated Age/Sex disaggregates	34,950
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	13,743
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,183
	Numerator: Indication: Routine	1,077
	Numerator: Indication: Targeted	29
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	



	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	



	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	1,151
	Denominator: Indication: Targeted	32
	Denominator: Preg/BF by Indication: Pregnant Routine	



	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	



	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	



	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	9
	Numerator Aggregated Age/Sex: 15+ Male	183
	Numerator Aggregated Age/Sex: <15 Female	8
	Numerator Aggregated Age/Sex: 15+ Female	906
	Denominator Aggregated Age/Sex: <15 Male	10
	Denominator Aggregated Age/Sex: 15+ Male	204
	Denominator Aggregated Age/Sex: <15 Female	9
	Denominator Aggregated Age/Sex: 15+ Female	960
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	132,181
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records	143,136



	in the past 12 months.	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication:	



	25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	132,181
	Numerator: Indication: Targeted	0
	Numerator: Preg/BF by Indication:	



	Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	143,136
	Denominator: Indication: Targeted	0
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by	



	Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	879
	Numerator Aggregated Age/Sex: 15+ Male	50,996
	Numerator Aggregated Age/Sex: <15 Female	1,073
	Numerator Aggregated Age/Sex: 15+ Female	83,030
	Denominator Aggregated Age/Sex: <15 Male	928
	Denominator Aggregated Age/Sex: 15+ Male	53,987
	Denominator Aggregated Age/Sex: <15 Female	1,122
	Denominator Aggregated Age/Sex: 15+ Female	84,647
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who	820



	are still alive and on treatment at 12 months after initiating ART	
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,004
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who	



	are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior	



	<p>to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	



	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	128
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	685
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
	Aggregated Age/Sex: 15+ Male	151



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	845
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	18,040
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	21,200



	follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female	



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	



	<p>Age/Sex: 10-14 Female          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 15-19 Female          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 20-24 Female          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 25-49 Female          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Age/Sex: 50+ Female          (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the</p>	



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male	116



	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,713
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	143
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,073
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,944
	Aggregated Age/Sex: <15 Female	172



	<p>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>12,943</p>



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7320	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
9915	American Society for Microbiology	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	570,000
11577	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
12817	Government of Botswana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13566	Tebelopele Voluntary Counseling and Testing	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,335,000



13669	Project Concern International	NGO	U.S. Agency for International Development	GHP-State	0
14707	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
14790	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
16714	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
16731	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	571,000
16736	Botswana Red Cross	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17005	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	70,000
17007	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	956,041
17274	University of Maryland	University	U.S. Department of Health and Human Services/Centers	GAP, GHP-State	4,214,962



			for Disease Control and Prevention		
17275	African Comprehensive HIV/AIDS Partnerships	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,100,000
17282	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17321	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	450,000
17322	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	1,000,000
17323	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	449,017
17544	JHPIEGO	University	U.S. Department of Defense	GHP-State	0
17845	Botswana Harvard AIDS Institute	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	385,000



			Prevention		
17846	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	431,146
17847	University of Pennsylvania	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,373,903
17861	Project Concern International	NGO	U.S. Agency for International Development	GHP-State	1,418,319
17862	FHI 360	NGO	U.S. Agency for International Development	GHP-State	900,000
17863	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	1,631,821
18163	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	3,067,000
18220	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	500,000
18221	Right To Care,	NGO	U.S. Agency for	GHP-State	500,000



	South Africa		International Development		
18252	TBD	TBD	Redacted	Redacted	Redacted
18253	TBD	TBD	Redacted	Redacted	Redacted
18458	Government of Botswana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7320</b>	<b>Mechanism Name: RPSO laboratory construction projects</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	7320		
<b>Mechanism Name:</b>	RPSO laboratory construction projects		
<b>Prime Partner Name:</b>	Regional Procurement Support Office/Frankfurt		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HMBL	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9915</b>	<b>Mechanism Name: Capacity building assistance for global HIV/AIDS microbiological labs</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society for Microbiology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 570,000</b>	
<b>Applied Pipeline Amount: 50,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 620,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	570,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 9915</b>
---------------------------



<b>Mechanism Name:</b>	<b>Capacity building assistance for global HIV/AIDS microbiological labs</b>		
<b>Prime Partner Name:</b>	<b>American Society for Microbiology</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	450,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	120,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11577</b>	<b>Mechanism Name: BDF, Department of Defense Support</b>
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 11577			
<b>Mechanism Name:</b> BDF, Department of Defense Support			
<b>Prime Partner Name:</b> U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 12817	<b>Mechanism Name:</b> Prevention, Strengthening Health and SI Systems and Access To Quality HIV/AIDS Services Through Support Programs Conducted By The Government Of Botswana
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Government of Botswana	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 1,592,799	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,592,799	
Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

Approved



(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	12817		
<b>Mechanism Name:</b>	Prevention, Strengthening Health and SI Systems and Access To		
<b>Prime Partner Name:</b>	Quality HIV/AIDS Services Through Support Programs Conducted By The Government Of Botswana Government of Botswana		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 13566</b>	<b>Mechanism Name: Expanding Access and Enhancing Quality of Integrated HTC Services</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Tebelopele Voluntary Counseling and Testing	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,335,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,335,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,335,000



**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	170,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	15,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG

**Budget Code Information**

<b>Mechanism ID:</b> 13566			
<b>Mechanism Name:</b> Expanding Access and Enhancing Quality of Integrated HTC Services			
<b>Prime Partner Name:</b> Tebelopele Voluntary Counseling and Testing			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	85,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	100,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	523
KP_PREV_DSD	Total estimated number of key population in the catchment area	747
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	513
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	15
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	732
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	51,159
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	91
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	21,180

	ONLY: 15+ Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	143
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	29,745
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	234
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	50,925
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	51,159
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	5
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,386
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	8
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,012
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	3,967
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	23,607
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	93
HTC_TST_DSD	Service Delivery Point (Facility): VCT	23,492
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	137
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	137
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	6
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	6
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	4
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	137
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	137
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	137
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	137
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	42
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	42
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	104
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	110
TX_PVLS_DSD	Numerator: Indication: Routine	104
TX_PVLS_DSD	Denominator: Indication: Routine	110
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	104
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	110
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	71
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	89
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	71
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	89



**Implementing Mechanism Details**

<b>Mechanism ID: 13669</b>	<b>Mechanism Name: OVC-Gender</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 13669</b>			
<b>Mechanism Name: OVC-Gender</b>			
<b>Prime Partner Name: Project Concern International</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0

**Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 14707</b>	<b>Mechanism Name: Ambassador's PEPFAR Small Grants Program</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 75,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 75,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	14707		
<b>Mechanism Name:</b>	Ambassador's PEPFAR Small Grants Program		
<b>Prime Partner Name:</b>	U.S. Department of State		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14790</b>	<b>Mechanism Name: Public Affairs/Public Diplomacy (PA/PD) Outreach</b>
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 150,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 150,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	14790		
<b>Mechanism Name:</b>	Public Affairs/Public Diplomacy (PA/PD) Outreach		
<b>Prime Partner Name:</b>	U.S. Department of State		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16714</b>	<b>Mechanism Name: Health Finance and Governance Project (HFG)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 43,891</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 43,891</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16714		
<b>Mechanism Name:</b>	Health Finance and Governance Project (HFG)		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16731</b>	<b>Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
<b>Total All Funding Sources: 571,000</b>	
<b>Applied Pipeline Amount: 400,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 971,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	571,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	171,000
----------------------------	---------

### Budget Code Information

<b>Mechanism ID:</b>	16731		
<b>Mechanism Name:</b>	Applying Science to Strengthen and Improve Systems (ASSIST)		
<b>Prime Partner Name:</b>	University Research Corporation, LLC		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	571,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16736</b>	<b>Mechanism Name: HIV care and treatment services in the Dukwi refugee camp</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Botswana Red Cross	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
<b>Total All Funding Sources: 100,000</b>	
<b>Applied Pipeline Amount: 300,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16736		
<b>Mechanism Name:</b>	HIV care and treatment services in the Dukwi refugee camp		
<b>Prime Partner Name:</b>	Botswana Red Cross		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	100,000	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	New on ART	16
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	320
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	10
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	204
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	9
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	97
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	3
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	3
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	3
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	320
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	10
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	204
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	9
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	97
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	19
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	301
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	320
TX_NEW_DSD	Number of adults and children newly enrolled on	60



	antiretroviral therapy (ART)	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	38
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	18
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	60
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	320
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	320
TX_PVLS_DSD	Numerator: Indication: Routine	259
TX_PVLS_DSD	Numerator: Indication: Targeted	29
TX_PVLS_DSD	Denominator: Indication: Routine	288
TX_PVLS_DSD	Denominator: Indication: Targeted	32
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	9
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	183
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	8
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	88
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	10
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	204
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	9
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	97
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	50
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	60
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	2



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18

### Implementing Mechanism Details

<b>Mechanism ID: 17005</b>	<b>Mechanism Name: Peace Corps HIV/AIDS Activities</b>
Funding Agency: PC	Procurement Type: Grant



Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 70,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 70,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	70,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	70,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID: 17005</b>			
<b>Mechanism Name: Peace Corps HIV/AIDS Activities</b>			
<b>Prime Partner Name: U.S. Peace Corps</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	70,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2017
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,620
PP_PREV_TA	Total number of people in the target population	309,513
PP_PREV_TA	Aggregated Age/sex: <15 Male	3,405
PP_PREV_TA	Aggregated Age/sex: 15+ Male	3,269
PP_PREV_TA	Aggregated Age/sex: <15 Female	3,541
PP_PREV_TA	Aggregated Age/sex: 15+ Female	3,405
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	486
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	688
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	1,500
OVC_SERV_TA	Age/Sex: 18+ Male	143
OVC_SERV_TA	Age/Sex: 18+ Female	183
OVC_SERV_TA	Sum of Age/Sex disaggregates	326

### Implementing Mechanism Details

<b>Mechanism ID: 17007</b>	<b>Mechanism Name: Development of Lab Network &amp; Society</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 956,041</b>	
<b>Applied Pipeline Amount: 97,489</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,053,530</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	956,041



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 17007</b>			
<b>Mechanism Name: Development of Lab Network &amp; Society</b>			
<b>Prime Partner Name: African Society for Laboratory Medicine</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	300,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	656,041	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17274</b>	<b>Mechanism Name: Capacity Building and Training</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,214,962</b>	
<b>Applied Pipeline Amount: 298,216</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,513,178</b>	



Funding Source	Funding Amount
GAP	912,832
GHP-State	3,302,130

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17274			
<b>Mechanism Name:</b> Capacity Building and Training			
<b>Prime Partner Name:</b> University of Maryland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,205,678	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	360,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	127,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,161,784	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	360,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2017
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,335
PMTCT_ART_TA	New on ART	1,404
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,775
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	16,335
PMTCT_STAT_TA	Number of new ANC and L&D clients	16,335
PMTCT_STAT_TA	By: Known positives at entry	727
PMTCT_STAT_TA	By: Number of new positives identified	3,673
PMTCT_STAT_TA	Sum of Positives Status disaggregates	4,400
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	178,918
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	1,145
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	67,099
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1,413
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	109,261
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	7,511
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	7,511
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	5,198
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	2,254
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	2,926
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	1,254



PMTCT_EID_TA	Sum of Infant Age disaggregates	4,180
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	49
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	21
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	178,918
TX_CURR_TA	Aggregated Age/Sex: <15 Male	3,269
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	65,286
TX_CURR_TA	Aggregated Age/Sex: <15 Female	4,044
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	106,319
TX_CURR_TA	Sum of Aggregated Age/Sex <15	7,313
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	171,605
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	178,918
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	34,950
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	1,186
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	12,293
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1,450
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	20,021
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	34,950
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	132,181
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	143,136
TX_PVLS_TA	Numerator: Indication: Routine	132,181
TX_PVLS_TA	Numerator: Indication: Targeted	0
TX_PVLS_TA	Denominator: Indication: Routine	143,136
TX_PVLS_TA	Denominator: Indication: Targeted	0



TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	879
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	50,996
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	1,073
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	83,030
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	928
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	53,987
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	1,122
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	84,647
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	256
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	301
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	156
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	113



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	184
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	18,040
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	21,200
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	116
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,713
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	143
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,073
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,944
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	172
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,943

**Implementing Mechanism Details**

<b>Mechanism ID: 17275</b>	<b>Mechanism Name: Voluntary Medical Male Circumcision</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Comprehensive HIV/AIDS Partnerships	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,100,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,100,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	17275		
<b>Mechanism Name:</b>	Voluntary Medical Male Circumcision		
<b>Prime Partner Name:</b>	African Comprehensive HIV/AIDS Partnerships		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,100,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,135
VMMC_CIRC_DSD	By Age: 10-14	771
VMMC_CIRC_DSD	By Age: 15-19	2,046
VMMC_CIRC_DSD	By Age: 20-24	1,008
VMMC_CIRC_DSD	By Age: 25-29	540
VMMC_CIRC_DSD	By Age: 30-49	770
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	3,825
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	5,135
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	4,110
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,025
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	1,335
VMMC_CIRC_TA	By Age: 10-14	200
VMMC_CIRC_TA	By Age: 15-19	532
VMMC_CIRC_TA	By Age: 20-24	262
VMMC_CIRC_TA	By Age: 25-49	141



VMMC_CIRC_TA	By Age: 30-49	200
VMMC_CIRC_TA	Sum of Age disaggregations (Prior to FY15)	1,135
VMMC_CIRC_TA	Sum of age disaggregates (FY15-Current)	1,194
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	1,068
VMMC_CIRC_TA	By circumcision technique: Device-based VMMC	267

**Implementing Mechanism Details**

<b>Mechanism ID: 17282</b>	<b>Mechanism Name: Blood Safety</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 47,900</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 47,900</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17282		
<b>Mechanism Name:</b>	Blood Safety		
<b>Prime Partner Name:</b>	American Association of Blood Banks		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HMBL	0	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17321</b>	<b>Mechanism Name: 4Children - Coordinating Comprehensive Care for Children</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:
<b>Total All Funding Sources: 450,000</b>	
<b>Applied Pipeline Amount: 37,500</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 487,500</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	450,000

### Cross-Cutting Budget Attribution(s)

Economic Strengthening	20,000
Education	20,000

### Budget Code Information

<b>Mechanism ID: 17321</b>			
<b>Mechanism Name: 4Children - Coordinating Comprehensive Care for Children</b>			
<b>Prime Partner Name: Catholic Relief Services</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Custom			



Care	HKID	450,000	0
------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17322</b>	<b>Mechanism Name: MEASURE Evaluation Phase IV</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,000,000</b>	
<b>Applied Pipeline Amount: 500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,000,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	400,000
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building



**Budget Code Information**

<b>Mechanism ID:</b> 17322			
<b>Mechanism Name:</b> MEASURE Evaluation Phase IV			
<b>Prime Partner Name:</b> University of North Carolina at Chapel Hill, Carolina Population Center			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,000,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17323	<b>Mechanism Name:</b> Challenge TB
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 449,017	
<b>Applied Pipeline Amount:</b> 26,956	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 475,973	
Funding Source	Funding Amount
GHP-State	449,017

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17323			
<b>Mechanism Name:</b> Challenge TB			
<b>Prime Partner Name:</b> KNCV Tuberculosis Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	449,017	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17544	<b>Mechanism Name:</b> BDF Prevention and Circumcision Program
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 0	
<b>Applied Pipeline Amount:</b> 1,225,000	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,225,000	
Funding Source	Funding Amount
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 17544			
<b>Mechanism Name:</b> BDF Prevention and Circumcision Program			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	5,618
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	1,370
VMMC_CIRC_DSD	By Age: 15-19	1,427
VMMC_CIRC_DSD	By Age: 20-24	1,652
VMMC_CIRC_DSD	By Age: 25-29	667
VMMC_CIRC_DSD	By Age: 30-49	450
VMMC_CIRC_DSD	By Age: 50+	52
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	4,501
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	5,618
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	5,618
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12	1,500



	months	
HTC_TST_DSD	Age/sex: 10-14 Male	135
HTC_TST_DSD	Age/sex: 15-19 Male	191
HTC_TST_DSD	Age/sex: 20-24 Male	829
HTC_TST_DSD	Age/sex: 25-49 Male	334
HTC_TST_DSD	Age/sex: 50+ Male	11
HTC_TST_DSD	Age/sex: 10-14 Female	0
HTC_TST_DSD	Age/sex: 15-19 Female	0
HTC_TST_DSD	Age/sex: 20-24 Female	0
HTC_TST_DSD	Age/sex: 25-49 Female	0
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,500
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	4
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	6
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	25
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	135
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,365
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	135
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,365



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,500
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	4
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	41
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	0
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	1,500

**Implementing Mechanism Details**

<b>Mechanism ID: 17845</b>	<b>Mechanism Name: Capacity Building through Training and Mentoring for Informatics</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Botswana Harvard AIDS Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 385,000</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 385,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	385,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17845			
<b>Mechanism Name:</b> Capacity Building through Training and Mentoring for Informatics			
<b>Prime Partner Name:</b> Botswana Harvard AIDS Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	385,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17846	<b>Mechanism Name:</b> Capacity Building through Training and Mentoring for Cervical Cancer
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 431,146	
<b>Applied Pipeline Amount:</b> 68,854	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 500,000	
Funding Source	Funding Amount
GHP-State	431,146

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17846			
<b>Mechanism Name:</b> Capacity Building through Training and Mentoring for Cervical Cancer			
<b>Prime Partner Name:</b> JHPIEGO			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	431,146	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17847	<b>Mechanism Name:</b> Capacity Building through Training and Mentoring for TB/HIV
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Pennsylvania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 1,373,903	
<b>Applied Pipeline Amount:</b> 226,097	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,600,000	
Funding Source	Funding Amount
GHP-State	1,373,903

**Cross-Cutting Budget Attribution(s)**

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	17847		
<b>Mechanism Name:</b>	Capacity Building through Training and Mentoring for TB/HIV		
<b>Prime Partner Name:</b>	University of Pennsylvania		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,373,903	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,583
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	5,583
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	196
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,002
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	199
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,186
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,434
TB_ART_TA	The number of registered new and relapse TB cases	3,434



	with documented HIV-positive status during TB treatment during the reporting period	
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	119
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,848
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	120
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,347

### Implementing Mechanism Details

<b>Mechanism ID: 17861</b>	<b>Mechanism Name: Botswana Comprehensive Care and Support for Orphans and Vulnerable Children Project (former OVC TBD)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Project Concern International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,418,319</b>	
<b>Applied Pipeline Amount: 1,680,542</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,098,861</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,418,319



### Cross-Cutting Budget Attribution(s)

Water	50,000
Human Resources for Health	150,000
Food and Nutrition: Policy, Tools, and Service Delivery	180,000
Food and Nutrition: Commodities	50,000
Education	200,000
Economic Strengthening	250,000
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Gender: GBV	150,000
Focus Area:	GBV Prevention

### Budget Code Information

<b>Mechanism ID:</b>	17861		
<b>Mechanism Name:</b>	Botswana Comprehensive Care and Support for Orphans and Vulnerable Children Project (former OVC TBD)		
<b>Prime Partner Name:</b>	Project Concern International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	1,418,319	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR	10,340



	OVC programs for children and families affected by HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	5,108
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	5,232

### Implementing Mechanism Details

<b>Mechanism ID: 17862</b>	<b>Mechanism Name: Linkages Across the Continuum of HIV Services for Key Populations Affected by HIV (LINKAGES) Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

<b>Total All Funding Sources: 900,000</b>	
<b>Applied Pipeline Amount: 674,437</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,574,437</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	900,000

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	600,566
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Gender: GBV	189,601
Focus Area:	GBV Prevention



### Budget Code Information

<b>Mechanism ID:</b>	17862		
<b>Mechanism Name:</b>	Linkages Across the Continuum of HIV Services for Key Populations Affected by HIV (LINKAGES) Project		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	171,012	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	228,988	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	4,035
KP_PREV_DSD	Total estimated number of key population in the catchment area	5,763
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	722
KP_PREV_DSD	By key population type: Female sex workers (FSW)	3,313



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	1,032
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	4,731
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,796
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	531
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,265
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	0
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	2,796
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,796
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	132
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	558
HTC_TST_DSD	Service Delivery Point (Community): Homebased	230

	testing	
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	855
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	0
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	0
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	259
HTC_TST_DSD	Service Delivery Point (Facility): VCT	1,452
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	0
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	564
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	0
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	564
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	564
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	814
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	814
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	814
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	814
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	305



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	305
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	305
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	610
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	643
TX_PVLS_DSD	Numerator: Indication: Routine	610
TX_PVLS_DSD	Denominator: Indication: Routine	643
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	610
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	0
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	643
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	372
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	465
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	372
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	465

### Implementing Mechanism Details

<b>Mechanism ID: 17863</b>	<b>Mechanism Name: Advancing Partners and Communities Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



<b>Total All Funding Sources: 1,631,821</b>	
<b>Applied Pipeline Amount: 3,008,279</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,640,100</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,631,821

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	593,211
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Monitoring and Evaluation
Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**

<b>Mechanism ID:</b>	<b>17863</b>
<b>Mechanism Name:</b>	<b>Advancing Partners and Communities Project</b>
<b>Prime Partner Name:</b>	<b>John Snow, Inc.</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,631,821	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,529
PP_PREV_DSD	Total number of people in the target population	5,529
PP_PREV_DSD	Aggregated Age/sex: <15 Male	205
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	510
PP_PREV_DSD	Aggregated Age/sex: <15 Female	1,382
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	3,432
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	56,421
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	4,713
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,837
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,990
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	23,766
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	9,703
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	46,603
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	56,306
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	226
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,531



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	318
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,595
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	33,349
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	6,484
HTC_TST_DSD	Service Delivery Point (Community): Other	16,473

**Implementing Mechanism Details**

<b>Mechanism ID: 18163</b>	<b>Mechanism Name: Technical assistance to strengthen government health systems</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,067,000</b>	
<b>Applied Pipeline Amount: 1,578,799</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,645,799</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,067,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**



<b>Mechanism ID:</b> 18163			
<b>Mechanism Name:</b> Technical assistance to strengthen government health systems			
<b>Prime Partner Name:</b> University of Washington			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	572,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	585,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,610,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	160,940
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,069
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	29,422
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,240
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	121,209
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,309
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	150,631
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	160,940



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	80
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	4,693
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	180
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	11,137
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	150,953
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	8,851
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	1,136
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,723
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,446
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	5,337
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,122
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	26,818
HTC_TST_TA	Sum of Aggregated Age/Sex <15	2,568
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	32,155
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	34,723
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	15
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,421
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	54
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	3,041
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	31,235



HTC_TST_TA	Service Delivery Point (Facility): PMTCT	3,255
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	233

**Implementing Mechanism Details**

<b>Mechanism ID: 18220</b>	<b>Mechanism Name: Global Health Supply Chain Program</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 386,749</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 886,749</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	18220		
<b>Mechanism Name:</b>	Global Health Supply Chain Program		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	500,000	0



### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18221</b>	<b>Mechanism Name: EQUIP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	
<b>Applied Pipeline Amount: 100,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 600,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18221		
<b>Mechanism Name:</b>	EQUIP		
<b>Prime Partner Name:</b>	Right To Care, South Africa		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	500,000	0

### Implementing Mechanism Indicator Information

Approved



(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18252</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18253</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18458</b>	<b>Mechanism Name: BCPP</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Government of Botswana	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18458		
<b>Mechanism Name:</b>	BCPP		
<b>Prime Partner Name:</b>	Government of Botswana		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	36,050
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	18,806
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	14,005
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,823
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	12,605



	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
--	---	--

**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		123,600		0	123,600	123,600
ICASS		638,914		0	638,914	638,914
Management Meetings/Professional Development		144,000		0	144,000	144,000
Non-ICASS Administrative Costs		446,900		0	446,900	446,900
Staff Program Travel		106,274		0	106,274	106,274
USG Staff Salaries and Benefits - Internationally Recruited		370,147		460,363	370,147	830,510
USG Staff Salaries and Benefits - Locally Recruited		258,237		306,908	258,237	565,145



<b>Total</b>	<b>0</b>	<b>2,088,072</b>	<b>0</b>	<b>767,271</b>	<b>2,088,072</b>	<b>2,855,343</b>
--------------	----------	------------------	----------	----------------	------------------	------------------

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		0		25,151	0	25,151
ICASS		0		22,959	0	22,959
Management Meetings/Professional Development		0		17,250	0	17,250
Staff Program Travel		0		28,755	0	28,755
USG Staff Salaries and Benefits - Locally Recruited		0		38,885	0	38,885
<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>133,000</b>	<b>0</b>	<b>133,000</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost	GAP	GHP-State	GHP-USAID	Applied	Total	Total All
-------------	-----	-----------	-----------	---------	-------	-----------



of Doing Business				Pipeline		Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		0		187,706	0	187,706
Computers/IT Services		0		77,577	0	77,577
ICASS		0		1,517,148	0	1,517,148
Management Meetings/Professional Development		0		21,000	0	21,000
Non-ICASS Administrative Costs		0		100,000	0	100,000
Non-ICASS Motor Vehicles		0		75,000	0	75,000
Staff Program Travel		0		395,000	0	395,000
USG Staff Salaries and Benefits - Internationally Recruited	1,283,418			559,331	1,283,418	1,842,749
USG Staff Salaries and Benefits - Locally Recruited	0	0		1,858,820	0	1,858,820
<b>Total</b>	<b>1,283,418</b>	<b>0</b>	<b>0</b>	<b>4,791,582</b>	<b>1,283,418</b>	<b>6,075,000</b>



### U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		0		3,000	0	3,000
Computers/IT Services		0		5,000	0	5,000
ICASS		62,651		10,000	62,651	72,651
Management Meetings/Professional Development		0		5,000	0	5,000
Non-ICASS Administrative Costs		0		15,000	0	15,000
Staff Program Travel				50,000	0	50,000
USG Staff Salaries and Benefits - Locally Recruited		0		87,000	0	87,000
<b>Total</b>	<b>0</b>	<b>62,651</b>	<b>0</b>	<b>175,000</b>	<b>62,651</b>	<b>237,651</b>

### U.S. Peace Corps



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services		2,000		0	2,000	2,000
ICASS		3,000		0	3,000	3,000
Institutional Contractors				0	0	0
Management Meetings/Professional Development		0		50,000	0	50,000
Non-ICASS Administrative Costs		144,000		0	144,000	144,000
Peace Corps Volunteer Costs		700,000		850,000	700,000	1,550,000
Staff Program Travel		73,000		0	73,000	73,000
USG Staff Salaries and Benefits - Locally Recruited		408,000		0	408,000	408,000
<b>Total</b>	<b>0</b>	<b>1,330,000</b>	<b>0</b>	<b>900,000</b>	<b>1,330,000</b>	<b>2,230,000</b>